You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,292,724


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,292,724
Title: Intraocular anticoagulant including antithrombin III and method of administration
Abstract:An intraocular anticoagulant including antithrombin III is applicable as an injection into the ocular chamber of the eye at the time of cataract surgery, intraocular lens implant surgery, and other ocular surgeries. The anticoagulant prevents fibrin deposits from forming on the intraocular lens surface after surgery and avoids postoperative viscoelastic material inducing transient elevation in intraocular pressure.
Inventor(s): Kita; Kiyoshi (Honmachi, Shibuyaku, Tokyo, JP)
Assignee:
Application Number:07/904,506
Patent Claims:1. A method of preventing fibrin clot formation on an intraocular lens surface, comprising the step of:

administering antithrombin III by injection into an ocular chamber during cataract and intraocular lens implant surgery.

2. A method of improving intracameral hypercoagulability, comprising the steps of:

administrating antithrombin III into a human ocular chamber and vitreous cavity.

3. A method of preventing fibrin clot formation on the intraocular lens surface and viscoelastic material-inducing elevation in intraocular pressure in a patient in need thereof, comprising the step of:

administering antithrombin III in an amount effective to prevent the fibrin clot formation on the intraocular lens surface by injection into an ocular chamber during cataract and intraocular lens implant surgery in which a viscoelastic material is used.

4. A method of improving intracameral hypercoagulability and viscoelastic material-inducing elevation in intraocular pressure in a patient in need thereof, comprising the step of:

administering antithrombin III in an amount effective to prevent the intracameral hypercoagulability during eye surgery in which a viscoelastic material is used.

5. The method as recited in claim 4, wherein the administering step comprises the step of:

administering the antithrombin III to the ocular chamber.

6. The method as recited in claim 4, wherein the administering step comprises the step of:

administering the antithrombin III to the vitreous cavity.

7. A method of preventing fibrin clot formation and viscoelastic material-induced elevation of intraocular pressure in a patient in need thereof, comprising the steps of:

forming a solution including antithrombin III in an amount effective to prevent viscoelastic material-induced elevation of intraocular pressure; and

administering the solution to the ocular chamber during eye surgery in which a viscoelastic material is used.

8. A method of preventing fibrin clot formation and viscoelastic material-induced elevation of intraocular pressure in a patient in need thereof, comprising the steps of:

forming a solution including antithrombin III in an amount effective to prevent viscoelastic material-induced elevation of intraocular pressure; and

administering the solution to the vitreous cavity during eye surgery in which a viscoelastic material is used.

9. The method as recited in claim 3, further comprising the step of selecting the viscoelastic material from the group consisting of a sodium hyaluronate solution, natural methylcellulose solution and collagen solution.

10. The method as recited in claim 4, further comprising the step of selecting the viscoelastic material from the group consisting of a sodium hyaluronate solution, natural methylcellulose solution and collagen solution.

11. The method as recited in claim 5, further comprising the step of selecting the viscoelastic material from the group consisting of a sodium hyaluronate solution, natural methylcellulose solution and collagen solution.

12. The method as recited in claim 6, further comprising the step of selecting the viscoelastic material from the group consisting of a sodium hyaluronate solution, natural methylcellulose solution and collagen solution.

13. The method as recited in claim 7, further comprising the step of selecting the viscoelastic material from the group consisting of a sodium hyaluronate solution, natural methylcellulose solution and collagen solution.

14. The method as recited in claim 8, further comprising the step of selecting the viscoelastic material from the group consisting of a sodium hyaluronate solution, natural methylcellulose solution and collagen solution.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.